You are subscribed to the FormularyWatch.

Formulary

eNewsletter Subscribe

February 25, 2015

Web Version  | Share with a colleague

Facebook Like Twitter Tweet

Today's Headlines

FDA clears closure system to permanently treat varicose veins

FDA has approved VenaSeal closure system (Covidien LLC and Medtronic) to permanently treat varicose veins of the legs. » Details

Actavis gains final FDA approval for generic Subutex

Actavis has received final approval from FDA on its Abbreviated New Drug Application for a generic version of Reckitt Benckiser's Subutex (buprenorphine 2-mg and 8-mg sublingual tablets) indicated for treatment of opioid dependence. » More

Continuing Education

New and emerging therapies for the treatment of diabetes

This month and next month pharmacists will be able to learn about the latest developments in diabetes treatment and management. Pharmacists can earn up to 4 hours of CPE credit with two monthly knowledge-based activities from the University of Connecticut School of Pharmacy and Drug Topics.

The goal of this month's activity is to discuss new and emerging medications for the treatment of diabetes.

Read/print the article: Click here

Take the test: Click here to log in with the Session Code 15DT15-WKX27.


Announcement: Our CE activities have moved to a new learning management system to better serve you. The login to the Online CE Center is https://web2.uconn.edu/pharmacyce/login.php. All current user registration information has been uploaded for your convenience. Current users do not need to register. To review your registration page to ensure the data is up to date or to register, go to https://web2.uconn.edu/pharmacyce/program_register.php. For a full list of courses, go to http://pharmacy.uconn.edu/academics/ce/drug-topics-and-uconn-ce/

EDITOR'S PICK

Develop a drug formulary for pain treatment in women of reproductive age

When developing drug formularies for pain treatment in women of reproductive age, formulary managers should follow 4 important steps. » Read more.

POLL:

A new class of biologics in the PCSK9 Inhibitors likely will be approved for treating high cholesterol. How are you preparing?

 

RELATED ARTICLES

Avoiding pitfall of venous disease requires deliberate approach

FDA approves abuse-deterrent labeling for Embeda

RESOURCES

Latest Clinical News

Powered by Modern Medicine Advanstar Medical Communications Group